#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This article discusses CBD-dominant full spectrum distillates in US cannabis products, containing approximately 67% to 79% CBD and various minor cannabinoids. The study found that these products may have inconsistent potency due to variable extraction methods and lack of regulatory oversight. Clinicians should be aware of potential variability in product quality and advise patients accordingly when considering CBD-based treatments.
🔬 In the context of evolving cannabis regulations and product offerings, an article titled “US Cannabis at a Crossroads” highlights research on CBD-dominant full spectrum distillates. These products contain a significant percentage (67%-79%) of CBD, along with minor cannabinoids. While the potential therapeutic benefits of these products are intriguing for healthcare providers, it’s crucial to acknowledge the complexity and variability in their composition. Confounders such as the presence of trace amounts of THC, varying concentrations of other cannabinoids, and inconsistencies in manufacturing processes may impact clinical outcomes. In practice, this underscores the need for ongoing education and vigilance when counseling patients about CBD products. Healthcare providers should emphasize the importance of discussing product sources, dosage, and potential interactions with other medications before recommending these treatments.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Read next
